CROCETTI, LETIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.086
EU - Europa 4.163
AS - Asia 2.815
SA - Sud America 311
Continente sconosciuto - Info sul continente non disponibili 215
AF - Africa 61
OC - Oceania 35
Totale 12.686
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.989
PL - Polonia 1.640
RU - Federazione Russa 1.001
IT - Italia 707
CN - Cina 702
SG - Singapore 702
HK - Hong Kong 586
VN - Vietnam 283
BR - Brasile 248
KR - Corea 221
IE - Irlanda 198
SE - Svezia 188
FI - Finlandia 89
FR - Francia 87
DE - Germania 78
GB - Regno Unito 78
IN - India 73
BD - Bangladesh 65
CA - Canada 63
ID - Indonesia 52
AU - Australia 35
JP - Giappone 25
AR - Argentina 24
JO - Giordania 23
BE - Belgio 22
NL - Olanda 21
ES - Italia 17
MX - Messico 16
CI - Costa d'Avorio 13
TR - Turchia 12
ZA - Sudafrica 12
IQ - Iraq 11
UA - Ucraina 11
EC - Ecuador 10
PK - Pakistan 9
NG - Nigeria 8
EG - Egitto 7
CL - Cile 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
BO - Bolivia 5
CO - Colombia 5
KZ - Kazakistan 5
PY - Paraguay 5
TW - Taiwan 5
CH - Svizzera 4
DZ - Algeria 4
IR - Iran 4
KE - Kenya 4
LV - Lettonia 4
MA - Marocco 4
CR - Costa Rica 3
CW - ???statistics.table.value.countryCode.CW??? 3
NP - Nepal 3
OM - Oman 3
PH - Filippine 3
PS - Palestinian Territory 3
SA - Arabia Saudita 3
SV - El Salvador 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AL - Albania 2
AT - Austria 2
BJ - Benin 2
BY - Bielorussia 2
HN - Honduras 2
LK - Sri Lanka 2
NI - Nicaragua 2
NO - Norvegia 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
HT - Haiti 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MD - Moldavia 1
MM - Myanmar 1
MY - Malesia 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
Totale 12.473
Salva come PNG Salva come JPEG
Città #
Warsaw 1.636
Santa Clara 1.159
Ashburn 623
Hong Kong 533
Singapore 513
Fairfield 323
San Jose 299
Seoul 218
Dublin 196
Hefei 194
Chandler 193
Seattle 165
Council Bluffs 158
Woodbridge 138
Florence 135
Beijing 132
Cambridge 121
Ann Arbor 116
Houston 113
Wilmington 107
Milan 93
Buffalo 90
Ho Chi Minh City 81
Altamura 78
Dallas 77
Lawrence 77
Los Angeles 71
Hanoi 63
Rome 62
Lauterbourg 55
Moscow 52
Princeton 52
The Dalles 44
Jakarta 43
Helsinki 36
Mumbai 36
Munich 32
Melbourne 31
New York 31
Shanghai 30
Kent 29
Boston 28
Medford 25
Paris 25
Boardman 24
Tokyo 23
Dong Ket 22
Brussels 21
San Diego 19
Bologna 18
Lappeenranta 18
London 18
São Paulo 17
Clifton 15
Frankfurt am Main 15
Orem 15
Naples 14
Toronto 14
Abidjan 13
Chicago 13
Turku 13
Jacksonville 12
Palermo 12
Barcelona 11
Haiphong 11
Phoenix 11
Redondo Beach 11
Turin 11
Austin 10
Brooklyn 10
Da Nang 10
Guangzhou 10
West Jordan 10
Yubileyny 9
Amsterdam 8
Chennai 8
Figino 8
Hillsboro 8
Johannesburg 8
Miano 8
Tianjin 8
Abuja 7
Baghdad 7
Bengaluru 7
Genoa 7
Norwalk 7
Padua 7
Shenzhen 7
Belo Horizonte 6
Durham 6
Falls Church 6
Gavirate 6
Hải Dương 6
Izmir 6
Manchester 6
Mexico City 6
Montreal 6
Rio de Janeiro 6
Salt Lake City 6
Vancouver 6
Totale 8.920
Salva come PNG Salva come JPEG
Nome #
Isoxazolo-5(2H)-one: a new scaffold for potent human neutrophil elastase (HNE) inhibitors 351
Synthesis, HPLC enantioresolution and X-ray analysis of a new series of C5-methyl pyridazines as N-formyl peptide receptor (FPR) agonists 345
Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase 330
Synthesis and analytical characterization of new thiazol-2-(3H)-ones as human neutrophil elastase (HNE) inhibitors 325
Synthesis and evaluation as PDE4 inhibitors of pyrimidine-2,4-dione derivatives 315
Identification of a new pyrazolo[1,5-a]quinazoline ligand highly affine to γ-aminobutyric type A (GABAA) receptor subtype with anxiolytic-like and antihyperalgesic activity 305
Design, synthesis and evaluation of N-benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase 303
Synthesis and evaluation as antitubercular agents of 5-arylethenyl and 5-(hetero)aryl-3-isoxazolecarboxylate 301
Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists. 299
Synthesis and pharmacological evaluation of new pyridazin-based thioderivatives as formyl peptide receptor (FPR) agonists 282
α2 Adrenoceptor: a Target for Neuropathic Pain Treatment 280
2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists. 277
New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4-(3H)-ones fluoroderivatives as human A1 adenosine receptor ligands 266
Synthesis, enantioresolution and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. 266
Synthesis of five and six-membered heterocycles bearing an arylpiperazinylalkyl side chain as orally active antinociceptive agents 258
Synthesis and pharmacological evaluation of indole derivatives as deaza analogues of potent human neutrophil elastase inhibitors 252
Synthesis and pharmacological evaluation of novel GABAA subtype receptor ligands with potential anxiolytic-like and anti-hyperlagesic effect 243
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022 233
Synthesis, biological evaluation, and molecular modelling studies of potent human neutrophil elastase (HNE) inhibitors 227
Synthesis of five and six-membered N-phenylacetamido substituted heterocycles as formyl peptide receptor agonists 225
Synthesis of New GABAA Receptor Modulator with Pyrazolo[1,5-a]quinazoline (PQ) Scaffold 222
Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists. 216
1H-pyrrolo[2,3-b]pyridine: a new scaffold for human neutrophil elastase (HNE) inhibitors 211
Exploration of Nitrogen Heterocycle Scaffolds for the Development of Potent Human Neutrophil Elastase Inhibitors 206
Further modifications of 1H-pyrrolo[2,3-b]pyridine derivatives as inhibitors of human neutrophil elastase 202
Cinnoline derivatives as human neutrophil elastase inhibitors 198
1,5,6,7-Tetrahydro-4H-indazol-4-ones as human neutrophil elastase (HNE) inhibitors 195
Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: synthesis and evaluation of their phosphodiesterase 4 inhibitory activity 186
Design, Synthesis and Pharmacological Evaluation of New Quinoline-Based Panx-1 Channel Blockers 184
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases. 183
Protective and Pain-Killer Effects of AMC3, a Novel N-Formyl Peptide Receptors (FPRs) Modulator, in Experimental Models of Rheumatoid Arthritis 174
'Proximity frequencies' a new parameter to evaluate the profile of GABAAR modulators 169
Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis 169
Editorial: Serine protease inhibitors and their therapeutic applications 168
New 3-unsubstituted Isoxazolones as Potent Human Neutrophil Elastase Inhibitors: Synthesis and Molecular Dynamic Simulation 168
Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists 168
Anti-Inflammatory Activity of Pyrazolo[1,5-a]quinazolines 164
New 3,6-disubstituted pyrazolo[1,5-a]quinazolines as ligands to GABAA receptor subtype 157
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A1 adenosine receptor ligands 155
A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications 152
New Panx-1 Blockers: Synthesis, Biological Evaluation and Molecular Dynamic Studies 145
GABAA receptor subtype modulators in medicinal chemistry: an updated patent review (2014-present) 142
Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity 140
Ebselen analogues with dual human neutrophil elastase (HNE) inhibitory and antiradical activity 138
Design and synthesis of the first indole-based blockers of Panx-1 channel 138
Novel Sulfonamide Analogs of Sivelestat as Potent Human Neutrophil Elastase Inhibitors 137
4,5-Dihydro-5-Oxo-Pyrazolo[1,5-a]Thieno[2,3-c]Pyrimidine: A Novel Scaffold Containing Thiophene Ring. Chemical Reactivity and In Silico Studies to Predict the Profile to GABAA Receptor Subtype 136
3,8-Disubstituted Pyrazolo[1,5-a]quinazoline as GABAA Receptor Modulators: Synthesis, Electrophysiological Assays, and Molecular Modelling Studies 134
Pyrazolo[1,5-a]quinazoline scaffold as 5-deaza analogue of pyrazolo[5,1-c][1,2,4]benzotriazine system: synthesis of new derivatives, biological activity on GABAA receptor subtype and molecular dynamic study 131
GABAA receptor modulators with a pyrazolo[1,5-a]quinazoline core: synthesis, molecular modelling studies and electrophysiological assay 126
Pyridazin-3(2H)-one as New FABP4 Inhibitors Suggested by Molecular Growing Experiments 125
New insights on the arylpiperazinylalkyl pyridazinone ET1 as potent antinociceptive and anti-inflammatory agent 125
X-ray structural study of human neutrophil elastase inhibition with a series of azaindoles, azaindazoles and isoxazolones 124
New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration 122
Ligand Growing Experiments Suggested 4-amino and 4-ureido pyridazin-3(2H)-one as Novel Scaffold for FABP4 Inhibition 120
Synthesis of 3-Carboxy-6-sulfamoylquinolones and Mefloquine-Based Compounds as Panx1 Blockers: Molecular Docking, Electrophysiological and Cell Culture Studies 116
Repurposing strategies on pyridazinone-based series by pharmacophore- and structure-driven screening 115
Molecular manipulation of the 1,5,6,7-tetrahydro-4 H -indazol-4-one scaffold to obtain new human neutrophil elastase (HNE) inhibitors 112
PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes 111
Optimization of 4-amino-pyridazin-3(2H)-one as a valid core scaffold for FABP4 inhibitors 108
New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategies 106
Synthesis and inverse virtual screening of new bi-cyclic structures towards cancer-relevant cellular targets 101
Pyridinone Derivatives as Interesting Formyl Peptide Receptor (FPR) Agonists for the Treatment of Rheumatoid Arthritis 94
Synthesis and Anti‐Hyperalgesic Efficacy of MP‐103, a Non‐Racemic Enantiomeric Mixture of a New 1,4‐Diazabicyclo[4.3.0]nonan‐9‐one 91
Steered Molecular Dynamics Simulations Study on FABP4 Inhibitors 91
Polynitrogen Bicyclic and Tricyclic Compounds as PDE4 Inhibitors 66
Labeling Peptides with Radioiodine: An Overview of Traditional and Emerging Techniques 66
New benzyldiazepane derivatives able to reduce biofilm formation in Escherichia coli 56
Insights into the complexity of SARS-CoV-2 Mpro inhibition: Ebselen and its derivatives impair dimerisation of the enzyme 47
Recent breakthroughs in synthetic small molecules targeting SARS-CoV-2 Mpro from 2022 to 2024 45
Abnormal purinergic signaling contributes to development of renal cysts in autosomal dominant polycystic kidney disease 34
Discovery of Potent PDE4 Inhibitors with 3(2H)-Pyridazinone Scaffold: Synthesis, In Silico Studies and In Vitro/Vivo Evaluation 14
Totale 12.686
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.019
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.019
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022397 0 14 35 12 18 29 12 35 20 33 100 89
2022/2023986 96 233 47 71 54 170 126 56 85 5 31 12
2023/2024389 11 41 64 12 22 40 15 106 11 36 22 9
2024/20253.315 110 287 161 422 932 444 80 146 385 73 120 155
2025/20264.226 388 552 441 321 398 144 529 183 308 299 186 477
2026/2027252 153 99 0 0 0 0 0 0 0 0 0 0
Totale 12.686